3-氧代-2-(3-吡啶基甲基)丁酸乙酯 | 32798-45-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 中文名称: 3-氧代-2-(3-吡啶基甲基)丁酸乙酯
• 英文名称: ethyl 3-oxo-2-(3-pyridylmethyl)butanoate
• 英文别名: 3-oxo-2-pyridin-3-ylmethyl-butyric acid ethyl ester；ethyl α-(3-pyridylmethyl)acetoacetate；2-(3-Picolyl)acetessigsaeure-ethylester；ethyl 3-oxo-2-(pyridin-3-ylmethyl)butanoate
• CAS: 32798-45-1
• 化学式: C₁₂H₁₅NO₃
• 分子量: 221.256
• InChiKey: QHXZPYHSQPRBEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  56.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-氧代-2-(3-吡啶基甲基)丁酸乙酯 在 硫酸 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 [4-methyl-2-oxo-3-(pyridin-3-ylmethyl)chromen-7-yl] N,N-dimethylcarbamate
  参考文献：
  名称：

  Discovery and structure–activity relationship of coumarin derivatives as TNF-α inhibitors

  摘要：

  The discovery and structure-activity relationship of a novel series of coumarin-based TNF-alpha inhibitors is described. Starting from the initial lead la, various derivatives were prepared surrounding the coumarin core structure to optimize the in vitro inhibitory activity of TNF-alpha production by human peripheral blood mononuclear cells (hPBMC), stimulated by bacterial lipopolysaccharide (LPS). Selected compounds also demonstrated in vivo inhibition of TNF-alpha production in rats. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.022
• 作为产物：
  描述：

  3-吡啶甲醛 、 乙酰乙酸乙酯 在 三甲基氯硅烷 、 sodium iodide 作用下， 以 乙腈 为溶剂， 以29%的产率得到3-氧代-2-(3-吡啶基甲基)丁酸乙酯
  参考文献：
  名称：

  Me3SiCl-NaI-MeCN 试剂诱导活性亚甲基化合物与芳香醛的 One-PotC-芳基甲基化

  摘要：

  在三甲基氯硅烷-碘化钠-乙腈试剂存在下，活性亚甲基化合物与芳香醛反应得到 C-芳基甲基化产物，即还原的缩合产物，尽管与脂肪族伯醛或异丁醛反应得到烷基化产物或二氢呋喃。

  DOI：

  10.1246/bcsj.62.4072

文献信息

• [EN] 4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE 4H-[1,2,4]TRIAZOLO[5,1-B]PYRIMIDIN-7-ONE À TITRE D'ANTAGONISTES DES RÉCEPTEURS CCR2B
  申请人：ASTRAZENECA AB

  公开号：WO2011114148A1

  公开（公告）日：2011-09-22

  The present invention relates to novel compounds for use in the compositions, to processes for their preparation, to intermediates useful in their preparation and to their use as therapeutic agents. The present invention also relates to pharmaceutical compositions, which comprise compounds that act via antagonism of the CCR2b receptor for which MCP-1 is one of the known ligands and so may be used to treat inflammatory disease, atherosclerosis, diabetes, obesity, cancer, chronic obstructive pulmonary disease (COPD) rheumatoid arthritis and/or neuropathic pain, which is mediated by these receptors.

  本发明涉及用于组合物中的新化合物，用于它们的制备过程，用于它们的制备中有用的中间体以及它们作为治疗剂的用途。本发明还涉及包含通过对CCR2b受体的拮抗作用而起作用的化合物的药物组合物，其中MCP-1是已知的配体之一，因此可用于治疗由这些受体介导的炎症性疾病、动脉粥样硬化、糖尿病、肥胖症、癌症、慢性阻塞性肺病（COPD）、类风湿性关节炎和/或由这些受体介导的神经病痛。
• Pyrido[1,2-<i>a</i>]benzimidazole-Based Agents Active Against Tuberculosis (TB), Multidrug-Resistant (MDR) TB and Extensively Drug-Resistant (XDR) TB
  作者：Marco Pieroni、Suresh K. Tipparaju、Shichun Lun、Yang Song、A. Willem Sturm、William R. Bishai、Alan P. Kozikowski

  DOI：10.1002/cmdc.201000490

  日期：2011.2.7

  The struggle against tuberculosis (TB) is still far from over. TB, caused by Mycobacterium tuberculosis, is one of the deadliest infections worldwide. Co‐infection with human immunodeficiency virus (HIV) and the emergence of multidrug‐resistant tuberculosis (MDR‐TB) and extensively drug‐resistant tuberculosis (XDR‐TB) strains have further increased the burden for this disease. Herein, we report the

  抗击结核病的斗争还远未结束。结核病由结核分枝杆菌引起，是全世界最致命的感染之一。人类免疫缺陷病毒（HIV）的合并感染以及耐多药结核病（MDR-TB）和广泛耐药结核病（XDR-TB）菌株的出现进一步加重了该病的负担。在此，我们报告了2-(4-氯苄基)-3-甲基-1-氧代-1 H ,5 H -吡啶并[1,2- a ]苯并咪唑-4-甲腈作为有效抗结核药物的发现及其结构该分子的修饰导致类似物具有更高的效力和更低的毒性。许多这些衍生物在亚微摩尔浓度下也具有对抗耐药结核菌株的活性，并且对 Vero 细胞没有明显的毒性，从而强调了它们作为开发新抗结核药物的新型支架的价值。
• Substituted isocytosines having histamine H.sub.2 -antagonist activity
  申请人：Smith Kline & French Laboratories Limited

  公开号：US04154834A1

  公开（公告）日：1979-05-15

  The compounds are substituted isocytosines which are histamine H.sub.2 -antagonists. Two specific compounds of the present inventon are 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-5-(3-pyridylmethyl)-4-py rimidone and 2-[2-(3-bromo-2-pyridylmethylthio)ethylamino]-5-(4-pyridylmethyl)-4-pyrimi done.

  这些化合物是取代的异胞嘧啶，是组胺H.sub.2-拮抗剂。本发明的两种特定化合物是2-[2-(5-甲基-4-咪唑基甲硫基)乙基氨基]-5-(3-吡啶甲基)-4-吡咯酮和2-[2-(3-溴-2-吡啶甲硫基)乙基氨基]-5-(4-吡啶甲基)-4-吡咯酮。
• Heterocyclic alkyl 4-pyrimidones
  申请人：Smith Kline & French Laboratories Limited

  公开号：US04216318A1

  公开（公告）日：1980-08-05

  The compounds are substituted isocytosines which are histamine H.sub.2 -antagonists. Two specific compounds of the present invention are 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-5-(3-pyridylmethyl)-4-py rimidone and 2-[2-(3-bromo-2-pyridylmethylthio)-ethylamino]-5-(4-pyridylmethyl)-4-pyrim idone.

  这些化合物是取代的异胞嘧啶，它们是组胺H.sub.2-拮抗剂。本发明的两种特定化合物是2-[2-(5-甲基-4-咪唑基甲硫基)乙基氨基]-5-(3-吡啶甲基)-4-吡咯酮和2-[2-(3-溴-2-吡啶甲硫基)-乙基氨基]-5-(4-吡啶甲基)-4-吡咯酮。
• Thiazole derivatives as H2-receptor antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0083186A2

  公开（公告）日：1983-07-06

  and their pharmaceutically-acceptable salts are effective anti-ulcer agents.

  及其药学上可接受的盐类是有效的抗溃疡剂。